ArticleHaematologica2009
Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm.
Article in Haematologica, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 39 citations in OpenAlex.
- Practical diagnostic approach to assess myeloid and precursor cell neoplasms on trephine bone marrow biopsies: reflection of middle European reality.Journal of hematopathology · 2025Review
- A Rare Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Occurred in Postchemotherapy of Breast Cancer.Case reports in hematology · 2023Article
- Dendritic Cell Leukemia: a Review.Current oncology reports · 2020Review
- Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.Therapeutic advances in hematology · 2019Review
- Blastic Plasmacytoid Dendritic Cell Neoplasm.Current hematologic malignancy reports · 2018Review
- Early detection of transformation to BPDCN in a patient with MDS.Experimental hematology & oncology · 2018Article
- Blastic plasmacytoid dendritic cell neoplasm in children: A review of two cases.Molecular and clinical oncology · 2017Article
- Treatment of blastic plasmacytoid dendritic cell neoplasm.Hematology. American Society of Hematology. Education Program · 2016Review
- Diffuse lung metastases in a child with blastic plasmacytoid dendritic cell neoplasm and review.European journal of pediatrics · 2014Review
- Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.Haematologica · 2013Article
- Recent advances in bone marrow biopsy pathology.Journal of hematopathology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia carrying cytoplasmic mutated nucleophosmin (NPMc(+) AML) and blastic plasmacytoid dendritic cell neoplasm have been included as new entities in the 4(th) edition (2008) WHO classification of myeloid neoplasms. These conditions may show clinical and pathological overlapping features (leukemic and skin involvement, and expression of macrophage markers). In this study, we provide evidence that aberrant cytoplasmic dislocation of nucleophosmin - the immunohistochemical surrogate for NPM1 mutations - allows the two entities to be genetically separated. In fact, nucleophosmin is consistently cytoplasmic in NPMc(+) AML (because of the presence of NPM1 mutations), whilst it is nucleus-restricted (predictive of a germline NPM1 gene) in blastic plasmacytoid dendritic cell neoplasm. Our results clearly point cytoplasmic nucleophosmin (a full predictor of NPM1 mutations) as a new marker for distinguishing NPMc(+) AML and blastic plasmacytoid dendritic cell neoplasm, further clarify the cell of origin of NPMc(+) AML, and justify the inclusion of these pathological conditions as separate entities in the new WHO classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.